脑血管病是东方人死亡率最高的疾病之一,缺血性脑病占了相当大的比例。继罂粟碱,甲氨乙基吡啶(Betahistine)脑益嗪(Cinnarizinum)等试用于临床之后,国内新近试制成功尼卡的平(Nicardipine),即日本山之内药厂创制的Yc-93,为一高选择性强力脑血管扩张药。但在抗脑缺氧药研制方面,除了三磷酸腺苷、巴比妥类和苯妥因钠有一些实验报告之外,至今尚无符合临床要求的药品。为此,首先建立适宜于药物筛选的脑缺血缺氧模型是非常必要的。 Cerebral vascular disease is one of the most fatal diseases in the East, ischemic encephalopathy accounted for a large proportion. Following the papaverine, Betamistine, Cinnarizinum and other trials in the clinical trial, the domestic production of Nicardipine (Nicardipine), Japan’s Yamanouchi Pharmaceutical Factory created Yc-93, a high Selective strong cerebral vasodilator. However, in the development of anti-brain hypoxia drugs, in addition to some experimental reports of adenosine triphosphate, barbiturates and phenytoin sodium, so far no clinical requirements of the drug. Therefore, it is necessary to establish a model of cerebral ischemia and hypoxia suitable for drug screening.